News and Trends 29 Jun 2022 Global call for scientists and inventors to form new startup A fourth start-up but the first of its kind sees some high-profile companies join forces in a hunt for new global research talent. AION Labs, an Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) are focusing their start-up on the ‘prediction of clinical trial outcome in biomarker-stratified cancer patient […] June 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 Drug for childhood arthritis gets expanded approvals in the EU A drug that can reduce the risk of flare and disease activity in children with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) has been approved based on data from a clinical trial. The JUNIPERA trial, showing that Cosentyx (secukinumab) reduced the risk of flare and disease activity compared to placebo over two years in pediatric patients with […] June 29, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 ARCH Venture Partners launches $3B fund for biotech companies ARCH Venture Partners has announced the closing of ARCH Venture Fund XII, with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies. The new fund follows the January 2021 announcement of the $1.941 billion ARCH Venture Fund XI. “All the fundamental innovations in biotechnology are accelerating, with huge promise […] June 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 Encouraging results from respiratory diseases vaccine trial A biopharmaceutical company developing vaccines against infectious diseases has announced positive results for people with life threatening respiratory diseases. Icosavax says that in an interim phase 1/1b trial its vaccine IVX-121 has demonstrated robust immunological response to respiratory syncytial virus (RSV) in both young and older adult groups. The vaccine was generally tolerated with no […] June 29, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 Deal to advance treatment for autoimmune disease worth $97M MiroBio, which is developing checkpoint agonists to treat autoimmune disease, has announced the completion of a $97 million deal. The financing is being led by Medicxi with investments from OrbiMed and Monograph Capital and existing investors Oxford Science Enterprises, Samsara Biocapital, SR One and Advent Life Sciences. Funds will primarily be used to advance MiroBio’s […] June 29, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 Watch: Antibody Analytics opens new health sciences center A new facility dedicated to the advancement of medical research and drug development opened its doors recently in Motherwell, Scotland, as part of a major expansion. Antibody Analytics, one of Scotland’s authorities on immunology, officially cut the ribbon on its new health sciences research center. The unveiling of the new Antibody Analytics Discovery Centre, funded […] June 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Jun 2022 7 biotech books to dive into this summer From the unprecedented speed at which the COVID-19 vaccines were developed to the biggest fraud case in biotech history, to a sci-fi story set in a post-apocalyptic city, here are seven biotech books to check out this summer. With record-breaking heat waves announcing the start of summer, there has never been a better time to […] June 29, 2022 - 6 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
In Depth 28 Jun 2022 Protecting our food supply chain with precision fermentation Many nations are experiencing a food security crisis caused by geopolitical conflicts, extreme weather and supply chain disruption. A wave of precision fermentation companies is working to protect from future food price shocks by producing sustainable protein ingredients from microbes rather than traditional farms. The world is facing a protracted food security crisis with the […] June 28, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Time Partners closes £30M venture fund to back life sciences startups Time Partners Limited has announced the final closing of its first advised fund, Time Boost Capital I LP, a £30 million ($36.6 million) genomics venture fund to provide match funding to startups graduating from Illumina Accelerator Cambridge, UK. Since opening in July 2020, Illumina Accelerator Cambridge has launched 13 startups focused on harnessing genomics applications […] June 28, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Companies unite to bolster diagnostics for cancer and liver disease Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease and breast cancer have partnered in a bid to bolster noninvasive diagnostics for the conditions. IV Bio-holdings (IVBH), a clinical-stage bio-platform company that conceives, creates and scales first-generation precision health solutions that improves the detection, diagnosis and treatment of disease […] June 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Breast cancer drug recommended for approval A cancer drug from AstraZeneca and Daiichi Sankyo called Enhertu, that reduces the risk of disease progression or even death by 72%, has been recommended for approval in the European Union (EU). The drug containing trastuzumab deruxtecan is specifically engineered for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer treated with […] June 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 MRM Health starts pouchitis clinical trial MRM Health, a Belgian clinical-stage biopharmaceutical company, has received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a phase 2 trial with the novel next-generation optimized consortium therapy, MH002, in patients with pouchitis. MH002 is the first consortium therapy in which key disease-driving mechanisms guide therapeutic microbial […] June 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email